#virology #ViiVHealthcare #steatoticliverdisease #Dovato #2drugHIVregimens #3drugHIVregimens #PASODOBLEstudy #HIV1 #HIV #Biktarvy #ConferenceonRetrovirusesandOpportunisticInfections2026 #HIVinnovation #metabolichealthoutcome #longtermHIVtreatment
zurl.co/ESlts
zurl.co/ESlts
ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato - PharmaTimes
PASO DOBLE sub‑analysis indicates metabolic differences between 2‑drug and 3‑drug HIV regimens
pharmatimes.com
March 3, 2026 at 9:57 AM